Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis
- PMID: 26848160
- DOI: 10.1161/ATVBAHA.115.307136
Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis
Abstract
Objective: Small-molecule hypoxia-inducible factor prolyl 4-hydroxylase (HIF-P4H) inhibitors are being explored in clinical studies for the treatment of anemia. HIF-P4H-2 (also known as PHD2 or EglN1) inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. We studied here whether HIF-P4H-2 inhibition could also protect against atherosclerosis.
Approach and results: Atherosclerosis development was studied in low-density lipoprotein (LDL) receptor-deficient mice treated with an oral HIF-P4H inhibitor, FG-4497, and in HIF-P4H-2-hypomorphic/C699Y-LDL receptor-mutant mice, all mice being fed a high-fat diet. FG-4497 administration to LDL receptor-deficient mice reduced the area of atherosclerotic plaques by ≈50% when compared with vehicle-treated controls and also reduced their weight gain, insulin resistance, liver and white adipose tissue (WAT) weights, adipocyte size, number of inflammation-associated WAT macrophage aggregates and the high-fat diet-induced increases in serum cholesterol levels. The levels of atherosclerosis-protecting circulating autoantibodies against copper-oxidized LDL were increased. The decrease in atherosclerotic plaque areas correlated with the reductions in weight, serum cholesterol levels, and WAT macrophage aggregates and the autoantibody increase. FG-4497 treatment stabilized HIF-1α and HIF-2α and altered the expression of glucose and lipid metabolism and inflammation-associated genes in liver and WAT. The HIF-P4H-2-hypomorphic/C699Y-LDL receptor-mutant mice likewise had a ≈50% reduction in atherosclerotic plaque areas, reduced WAT macrophage aggregate numbers, and increased autoantibodies against oxidized LDL, but did not have reduced serum cholesterol levels.
Conclusions: HIF-P4H-2 inhibition may be a novel strategy for protecting against the development of atherosclerosis. The mechanisms involve beneficial modulation of the serum lipid profile and innate immune system and reduced inflammation.
Keywords: atherosclerosis; cholesterol; hypoxia; immunology; inflammation.
© 2016 American Heart Association, Inc.
Similar articles
-
Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1418-26. doi: 10.1161/ATVBAHA.112.249342. Epub 2012 Apr 19. Arterioscler Thromb Vasc Biol. 2012. PMID: 22516063
-
Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.Redox Biol. 2019 Apr;22:101145. doi: 10.1016/j.redox.2019.101145. Epub 2019 Feb 19. Redox Biol. 2019. PMID: 30802717 Free PMC article.
-
HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction.Diabetes. 2014 Oct;63(10):3324-33. doi: 10.2337/db14-0472. Epub 2014 May 1. Diabetes. 2014. PMID: 24789921
-
Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.Stroke. 2006 Jul;37(7):1923-32. doi: 10.1161/01.STR.0000226901.34927.10. Epub 2006 Jun 1. Stroke. 2006. PMID: 16741184 Review.
-
Hypoxia-Inducible Factor Prolyl 4-Hydroxylases and Metabolism.Trends Mol Med. 2018 Dec;24(12):1021-1035. doi: 10.1016/j.molmed.2018.10.004. Epub 2018 Nov 1. Trends Mol Med. 2018. PMID: 30391126 Review.
Cited by
-
Cholesterol and HIF-1α: Dangerous Liaisons in Atherosclerosis.Front Immunol. 2022 Mar 21;13:868958. doi: 10.3389/fimmu.2022.868958. eCollection 2022. Front Immunol. 2022. PMID: 35386720 Free PMC article. Review.
-
Hypoxia and hypoxia-inducible factors in diabetes and its complications.Diabetologia. 2021 Apr;64(4):709-716. doi: 10.1007/s00125-021-05380-z. Epub 2021 Jan 26. Diabetologia. 2021. PMID: 33496820 Free PMC article. Review.
-
Integrated systems biology approach identifies gene targets for endothelial dysfunction.Mol Syst Biol. 2023 Dec 6;19(12):e11462. doi: 10.15252/msb.202211462. Epub 2023 Nov 30. Mol Syst Biol. 2023. PMID: 38031960 Free PMC article.
-
Hypoxia-inducible factor-1α regulation of myeloid cells.J Mol Med (Berl). 2018 Dec;96(12):1293-1306. doi: 10.1007/s00109-018-1710-1. Epub 2018 Nov 1. J Mol Med (Berl). 2018. PMID: 30386909 Free PMC article. Review.
-
The Potential Role of Hypoxia-Inducible Factor-1 in the Progression and Therapy of Central Nervous System Diseases.Curr Neuropharmacol. 2022 Aug 3;20(9):1651-1666. doi: 10.2174/1570159X19666210729123137. Curr Neuropharmacol. 2022. PMID: 34325641 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases